352 related articles for article (PubMed ID: 21433318)
1. [Current diagnosis of myeloproliferative neoplasms (2008 WHO classification)].
Frenkel' MA
Klin Lab Diagn; 2011 Jan; (1):43-9. PubMed ID: 21433318
[TBL] [Abstract][Full Text] [Related]
2. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.
Vardiman J; Hyjek E
Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042
[TBL] [Abstract][Full Text] [Related]
3. The myeloproliferative neoplasms including the eosinophilia-related myeloproliferations associated with tyrosine kinase mutations: changes and issues in classification and diagnosis criteria.
Anastasi J
Semin Diagn Pathol; 2011 Nov; 28(4):304-13. PubMed ID: 22195408
[TBL] [Abstract][Full Text] [Related]
4. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
Tefferi A; Vardiman JW
Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
[TBL] [Abstract][Full Text] [Related]
5. [A revised 4 edition WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2017: myeloid neoplasms].
Kovrigina AM
Arkh Patol; 2018; 80(6):43-49. PubMed ID: 30585592
[TBL] [Abstract][Full Text] [Related]
6. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Barbui T; Thiele J; Gisslinger H; Kvasnicka HM; Vannucchi AM; Guglielmelli P; Orazi A; Tefferi A
Blood Cancer J; 2018 Feb; 8(2):15. PubMed ID: 29426921
[TBL] [Abstract][Full Text] [Related]
7. Advances in understanding and management of myeloproliferative neoplasms.
Vannucchi AM; Guglielmelli P; Tefferi A
CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
[TBL] [Abstract][Full Text] [Related]
8. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
9. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
Anastasi J
Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
[TBL] [Abstract][Full Text] [Related]
10. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
11. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
12. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
13. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD
Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394
[TBL] [Abstract][Full Text] [Related]
14. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
15. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
[TBL] [Abstract][Full Text] [Related]
16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
17. Pathology consultation on myeloproliferative neoplasms.
Schmidt AE; Oh ST;
Am J Clin Pathol; 2012 Jul; 138(1):12-9. PubMed ID: 22706852
[TBL] [Abstract][Full Text] [Related]
18. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA; Orazi A; Hasserjian R; Thiele J; Borowitz MJ; Le Beau MM; Bloomfield CD; Cazzola M; Vardiman JW
Blood; 2016 May; 127(20):2391-405. PubMed ID: 27069254
[TBL] [Abstract][Full Text] [Related]
19. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
20. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
